Alnylam Files to Begin Phase I Trial of Subcutaneous TTR Drug in UK
January 03, 2013
Alnylam Files to Begin Phase I Trial of Subcutaneous TTR Drug in UK
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam Starts Phase I Trial of Subcutaneous ATTR Drug
March 21, 2013 / Gene Silencing News - Reporting Positive Data on Conjugate Delivery Tech, Alnylam Preps IND for Subcutaneous ATTR Therapy
August 9, 2012 / Gene Silencing News - Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13
May 16, 2013 / Gene Silencing News - Alnylam to Release Phase II ATTR Data, Launch Expansion Trial in Coming Months
May 9, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Merck, BASF, and More
April 18, 2013 / Gene Silencing News